NASDAQ:ONCO Onconetix 5/20/2024 Earnings Report $0.35 -0.03 (-7.22%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Onconetix EPS ResultsActual EPS-$2,720.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOnconetix Revenue ResultsActual Revenue$0.70 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOnconetix Announcement DetailsQuarterDate5/20/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Onconetix Earnings HeadlinesOnconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with LabcorpMay 13, 2026 | quiverquant.comQOnconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation StudyMay 13, 2026 | globenewswire.comBNZI Update: Zacks Buy Rating Sparks Fresh Momentum!Banzai International (NASDAQ: BNZI) delivered full-year 2025 revenue of $12.2 million, a 169% year-over-year increase, with gross margins expanding to 81.9%. The company was recently upgraded to a Zacks Rank 2 (Buy) as analysts raised earnings estimates materially. A planned acquisition of ConnectAndSell is expected to add roughly $15 million in annual revenue, potentially more than doubling BNZI's current revenue base. With 150,000 customers and a unified AI-first platform, the company is building full-funnel capabilities across marketing and sales.May 18 at 1:00 AM | Huge Alerts (Ad)Onconetix Shareholders Approve Flexible Reverse Stock Split AuthorizationMay 8, 2026 | theglobeandmail.comOnconetix Reshapes Board Leadership With New Chairman, DirectorApril 24, 2026 | tipranks.comOnconetix: HRT financial, 10% owner, sells $110,169 in stockApril 23, 2026 | investing.comSee More Onconetix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email. Email Address About OnconetixOnconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.View Onconetix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Everspin Technologies the Next AI Edge Breakout?Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavault Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingRobinhood, SoFi, and Webull Are Telling Very Different StoriesViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised Outlook Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
